NCT05821361 is a Phase 2 clinical trial of HAIC+Cadonilimab+Bevacizumab in Unrescetable Hepatocellular Carcinoma, sponsored by Tianjin Medical University Cancer Institute and Hospital.

Who is sponsoring NCT05821361?

NCT05821361 is sponsored by Tianjin Medical University Cancer Institute and Hospital.

What drugs are being tested in NCT05821361?

Interventions in NCT05821361: HAIC+Cadonilimab+Bevacizumab.

What condition does NCT05821361 study?

NCT05821361 studies Unrescetable Hepatocellular Carcinoma.

Is NCT05821361 still recruiting?

NCT05821361 is currently status unknown. Last updated 20 April 2023.

Last reviewed 2023-04-20 · How we verify

NCT05821361

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

HAIC Combined With Cadonilimab and Bevacizumab as First-line Therapy in Unresectable Hepatocellular Carcinoma

Status unknown Phase 2 Last updated 20 April 2023

What this trial tests

Phase 2 trial testing HAIC+Cadonilimab+Bevacizumab in Unrescetable Hepatocellular Carcinoma in 30 participants. Status unknown.

Timeline

1 August 2023

Primary endpoint
1 August 2024

1 August 2025

Quick facts

Lead sponsor	Tianjin Medical University Cancer Institute and Hospital
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	30
Start date	1 August 2023
Primary completion	1 August 2024
Estimated completion	1 August 2025
Sites	1 location across China

Drugs / interventions tested

HAIC+Cadonilimab+Bevacizumab — full drug profile →

Conditions studied

Unrescetable Hepatocellular Carcinoma — all drugs for Unrescetable Hepatocellular Carcinoma →

Sponsor

Tianjin Medical University Cancer Institute and Hospital

Who can join

Adults 18 to 75, any sex, with Unrescetable Hepatocellular Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To evaluate the efficacy and safety of HAIC combined with Cadonilimab and bevacizumab as first-line therapy in Unresectable hepatocellular carcinoma

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Tianjin Medical University Cancer Institute and Hospital trials

Trials by the same sponsor.

NCT07493993 — Clinical Study on the Efficacy and Safety of Iparomlimab and Tuvonralimab Injection Combined With Nab-Paclitaxel in Neoa · Phase 2 · not yet recruiting
NCT07515469 — A Prospective, Single-Arm, Exploratory Study of the Safety and Efficacy of Neoadjuvant Treatment With QL1706, an Anti-PD · Phase 2 · not yet recruiting
NCT07475026 — A Study of Neoadjuvant Tislelizumab Plus Lenvatinib in Resectable HCC at High Risk of Recurrence · Phase 3 · not yet recruiting
NCT07510594 — A Phase II Study of Benmelstobart + Anlotinib + Chemotherapy as First-Line Treatment for LCNEC and EP-NEC · Phase 2 · not yet recruiting
NCT07528274 — Microwave Ablation Plus Tislelizumab and Docetaxel in Advanced NSCLC After First-Line Immunotherapy Failure · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05821361 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Tianjin Medical University Cancer Institute and Hospital
Last refreshed: 20 April 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05821361.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing